sibutramine

Sibutramine is a small molecule pharmaceutical drug originally developed for the treatment of obesity. It acts primarily as a serotonin–norepinephrine reuptake inhibitor (SNRI), with some dopamine reuptake inhibition. By inhibiting the reuptake of these neurotransmitters at neuronal synapses—mainly through its active metabolites M1 (desmethylsibutramine) and M2 (didesmethylsibutramine)—sibutramine increases levels of norepinephrine (~73% inhibition), serotonin (~54%), and dopamine (~16%) in the brain. This leads to enhanced satiety and reduced appetite. Unlike older anorectic agents such as amphetamines or fenfluramine that promote neurotransmitter release rather than inhibit their reuptake—and unlike other serotonergic appetite suppressants—sibutramine has low affinity for most monoamine receptors and does not act as a releasing agent or monoamine oxidase inhibitor[1][5][7]. The drug was approved by regulatory agencies in the late 1990s but has since been withdrawn from many markets due to cardiovascular safety concerns[2].

Brand names

MeridiaReductilSibutrexSirediaEctivaKES 524KES524KES-524ReductaseReduxadeSibutralAtenixDiet MaxFingrassIpograsMintagrasRegitrimSacietil NFSatonAccentAdisarBiomagButaslimButraminCetonidObenilPerfil

Other names

Aoquqing